Tema Neuroscience and Mental Health ETF (MNTL)
25.42
-0.04
(-0.16%)
USD |
NASDAQ |
May 16, 16:00
25.46
+0.04
(+0.16%)
After-Hours: 20:00
Price Chart
Key Stats
| Net Expense Ratio | Discount or Premium to NAV | Total Assets Under Management | 30-Day Average Daily Volume |
|---|---|---|---|
| 0.75% | 0.21% | 11.16M | 395.60 |
| Dividend Yield | Turnover Ratio | 1 Year Fund Level Flows | Max Drawdown (Since Inception) |
| 0.00% | -- | -- | Upgrade |
Basic Info
| Investment Strategy | |
| The investment seeks to provide long-term growth of capital. Under normal circumstances, the Tema Neuroscience and Mental Health ETF seeks to achieve its investment objective by investing at least 80% of its net assets, which include borrowings for investment purposes, in neuroscience and mental health companies. A company is generally considered to be a neuroscience or mental health company that derives at least 50% of revenues from neuroscience or neurology-related diseases, or mental health. The fund is non-diversified. |
| General | |
| Security Type | Exchange-Traded Fund |
| Equity Style | Mid Cap/Growth |
| Fixed Income Style | -- |
| Broad Asset Class | Sector Equity |
| Broad Category | Equity |
| Category Name | Health |
| Category Index | -- |
| Global Category Name | Healthcare Sector Equity |
| YCharts Categorization | Healthcare Equity |
| YCharts Benchmark | S&P 1500 Health Care (Sector) Total Return (^SP15HCSTR) |
| Prospectus Objective | Specialty - Unaligned |
| Fund Owner Firm Name | Tema Global Limited |
| Prospectus Benchmark Index | |
| N/A | 100.0% |
| Broad Asset Class Benchmark Index | |
| ^MSWNTR | 100.0% |
| Manager Tenure | |
| David Song | 0.27 yrs |
| Garrett Paolella | 0.27 yrs |
| Ryan Houlton | 0.27 yrs |
| Troy Cates | 0.27 yrs |
| Yuri Khodjamirian | 0.27 yrs |
Performance Versus Category
As of May 16, 2024. Returns for periods of 1 year and above are annualized.
Annual Total Returns Versus Peers
As of May 16, 2024.
Basic Info
| Investment Strategy | |
| The investment seeks to provide long-term growth of capital. Under normal circumstances, the Tema Neuroscience and Mental Health ETF seeks to achieve its investment objective by investing at least 80% of its net assets, which include borrowings for investment purposes, in neuroscience and mental health companies. A company is generally considered to be a neuroscience or mental health company that derives at least 50% of revenues from neuroscience or neurology-related diseases, or mental health. The fund is non-diversified. |
| General | |
| Security Type | Exchange-Traded Fund |
| Equity Style | Mid Cap/Growth |
| Fixed Income Style | -- |
| Broad Asset Class | Sector Equity |
| Broad Category | Equity |
| Category Name | Health |
| Category Index | -- |
| Global Category Name | Healthcare Sector Equity |
| YCharts Categorization | Healthcare Equity |
| YCharts Benchmark | S&P 1500 Health Care (Sector) Total Return (^SP15HCSTR) |
| Prospectus Objective | Specialty - Unaligned |
| Fund Owner Firm Name | Tema Global Limited |
| Prospectus Benchmark Index | |
| N/A | 100.0% |
| Broad Asset Class Benchmark Index | |
| ^MSWNTR | 100.0% |
| Manager Tenure | |
| David Song | 0.27 yrs |
| Garrett Paolella | 0.27 yrs |
| Ryan Houlton | 0.27 yrs |
| Troy Cates | 0.27 yrs |
| Yuri Khodjamirian | 0.27 yrs |